NGENLA (Somatrogon) ( DrugBank: Somatrogon )
1 disease
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 78 | Hypopituitarism | 1 |
78. Hypopituitarism
Clinical trials : 492 / Drugs : 341 - (DrugBank : 47) / Drug target genes : 45 - Drug target pathways : 100
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT05602766 (ClinicalTrials.gov) | February 6, 2023 | 27/10/2022 | Ngenla Subcutaneous Injection Special Investigation | Ngenla® Subcutaneous Injection Special Investigation | Growth Hormone Deficiency Without Epiphyseal Closure | Drug: NGENLA (Somatrogon) | Pfizer | NULL | Recruiting | N/A | 15 Years | All | 229 | Japan |